ElectroCore Earns Expanded 510(k) for Vagus Nerve Stimulation Therapy

March 30, 2020

The FDA has granted ElectroCore additional 510(k) clearance for its GammaCore vagus nerve stimulation device, clearing it for use in migraine prevention in adults.

The therapy uses gentle stimulation to activate the patient’s vagus nerve, which facilitates communication between the brain and other areas of the body and helps regulate pain.

The device is currently indicated for prevention of cluster headaches and for acute treatment of pain associated with episodic cluster headache and migraine headache in adult patients.

View today's stories